BACKGROUND:Heart failure (HF) with preserved left ventricular ejection fraction (HFPEF) is the most common form of HF in the older population. Exercise intolerance is the primary chronic symptom in patients with HFPEF and is a strong determinant of their reduced quality of life (QOL). Exercise training (ET) improves exercise intolerance and QOL in patients with HF with reduced ejection fraction (EF). However, the effect of ET in HFPEF has not been examined in a randomized controlled trial. METHODS AND RESULTS: This 16-week investigation was a randomized, attention-controlled, single-blind study of medically supervised ET (3 days per week) on exercise intolerance and QOL in 53 elderly patients (mean age, 70±6 years; range, 60 to 82 years; women, 46) with isolated HFPEF (EF ≥50% and no significant coronary, valvular, or pulmonary disease). Attention controls received biweekly follow-up telephone calls. Forty-six patients completed the study (24 ET, 22 controls). Attendance at exercise sessions in the ET group was excellent (88%; range, 64% to 100%). There were no trial-related adverse events. The primary outcome of peak exercise oxygen uptake increased significantly in the ET group compared to the control group (13.8±2.5 to 16.1±2.6 mL/kg per minute [change, 2.3±2.2 mL/kg per minute] versus 12.8±2.6 to 12.5±3.4 mL/kg per minute [change, -0.3±2.1 mL/kg per minute]; P=0.0002). There were significant improvements in peak power output, exercise time, 6-minute walk distance, and ventilatory anaerobic threshold (all P<0.002). There was improvement in the physical QOL score (P=0.03) but not in the total score (P=0.11). CONCLUSIONS:ET improves peak and submaximal exercise capacity in older patients with HFPEF.
RCT Entities:
BACKGROUND:Heart failure (HF) with preserved left ventricular ejection fraction (HFPEF) is the most common form of HF in the older population. Exercise intolerance is the primary chronic symptom in patients with HFPEF and is a strong determinant of their reduced quality of life (QOL). Exercise training (ET) improves exercise intolerance and QOL in patients with HF with reduced ejection fraction (EF). However, the effect of ET in HFPEF has not been examined in a randomized controlled trial. METHODS AND RESULTS: This 16-week investigation was a randomized, attention-controlled, single-blind study of medically supervised ET (3 days per week) on exercise intolerance and QOL in 53 elderly patients (mean age, 70±6 years; range, 60 to 82 years; women, 46) with isolated HFPEF (EF ≥50% and no significant coronary, valvular, or pulmonary disease). Attention controls received biweekly follow-up telephone calls. Forty-six patients completed the study (24 ET, 22 controls). Attendance at exercise sessions in the ET group was excellent (88%; range, 64% to 100%). There were no trial-related adverse events. The primary outcome of peak exercise oxygen uptake increased significantly in the ET group compared to the control group (13.8±2.5 to 16.1±2.6 mL/kg per minute [change, 2.3±2.2 mL/kg per minute] versus 12.8±2.6 to 12.5±3.4 mL/kg per minute [change, -0.3±2.1 mL/kg per minute]; P=0.0002). There were significant improvements in peak power output, exercise time, 6-minute walk distance, and ventilatory anaerobic threshold (all P<0.002). There was improvement in the physical QOL score (P=0.03) but not in the total score (P=0.11). CONCLUSIONS: ET improves peak and submaximal exercise capacity in older patients with HFPEF.
Authors: Dalane W Kitzman; William C Little; Peter H Brubaker; Roger T Anderson; W Gregory Hundley; Christian T Marburger; Bridget Brosnihan; Timothy M Morgan; Kathryn P Stewart Journal: JAMA Date: 2002-11-06 Impact factor: 56.272
Authors: W G Hundley; D W Kitzman; T M Morgan; C A Hamilton; S N Darty; K P Stewart; D M Herrington; K M Link; W C Little Journal: J Am Coll Cardiol Date: 2001-09 Impact factor: 24.094
Authors: Pairoj Rerkpattanapipat; W Gregory Hundley; Kerry M Link; Peter H Brubaker; Craig A Hamilton; Stephen N Darty; Timothy M Morgan; Dalane W Kitzman Journal: Am J Cardiol Date: 2002-12-01 Impact factor: 2.778
Authors: R B Devereux; M J Roman; J E Liu; T K Welty; E T Lee; R Rodeheffer; R R Fabsitz; B V Howard Journal: Am J Cardiol Date: 2000-11-15 Impact factor: 2.778
Authors: G H Guyatt; M J Sullivan; P J Thompson; E L Fallen; S O Pugsley; D W Taylor; L B Berman Journal: Can Med Assoc J Date: 1985-04-15 Impact factor: 8.262
Authors: Philip M Mottram; Brian Haluska; Rodel Leano; Diane Cowley; Michael Stowasser; Thomas H Marwick Journal: Circulation Date: 2004-07-26 Impact factor: 29.690
Authors: Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Scott L Hummel; E Mitchell Seymour; Robert D Brook; Theodore J Kolias; Samar S Sheth; Hannah R Rosenblum; Joanna M Wells; Alan B Weder Journal: Hypertension Date: 2012-10-01 Impact factor: 10.190
Authors: Sara Maldonado-Martín; Peter H Brubaker; Joel Eggebeen; Kathryn P Stewart; Dalane W Kitzman Journal: Arch Phys Med Rehabil Date: 2016-09-28 Impact factor: 3.966
Authors: Muaz M Abudiab; Margaret M Redfield; Vojtech Melenovsky; Thomas P Olson; David A Kass; Bruce D Johnson; Barry A Borlaug Journal: Eur J Heart Fail Date: 2013-02-20 Impact factor: 15.534